At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VOR Vor Biopharma Inc.
Trading 12-18 12:55:36 EST
13.37
-0.89
-6.28%
High14.84Low12.41Vol1.52M
Open14.68D1 Closing14.26Amplitude17.04%
Mkt Cap292.84MTradable Cap253.55MTotal Shares21.91M
T/O20.02MT/O Rate8.00%Tradable Shares18.97M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks
Reuters  ·  12-17 23:40
BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks
Vor Biopharma Initiated at Buy by TD Cowen
Dow Jones  ·  12-17 23:30
Vor Biopharma Initiated at Buy by TD Cowen
Vor Biopharma Shares up 1.6% After TD Cowen Initiates Coverage With Buy Rating
THOMSON REUTERS  ·  12-17 22:31
Vor Biopharma Shares up 1.6% After TD Cowen Initiates Coverage With Buy Rating
BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse
Reuters  ·  12-17 22:14
BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse
BUZZ-Vor Bio jumps after TD Cowen initiates coverage with 'buy'
Reuters  ·  12-17 21:13
BUZZ-Vor Bio jumps after TD Cowen initiates coverage with 'buy'
TD Cowen Initiates Vor Biopharma at Buy
MT Newswires Live  ·  12-17 20:48
TD Cowen Initiates Vor Biopharma at Buy
Vor Biopharma Inc : TD Cowen Initiates Coverage With Buy Rating
THOMSON REUTERS  ·  12-17 18:41
Vor Biopharma Inc : TD Cowen Initiates Coverage With Buy Rating
Vor Biopharma Launches $150 Million Private Placement; Shares Rise
MT Newswires Live  ·  12-15
Vor Biopharma Launches $150 Million Private Placement; Shares Rise
BRIEF-Vor Bio Announces $150 Million Private Placement
Reuters  ·  12-15
BRIEF-Vor Bio Announces $150 Million Private Placement
BUZZ-U.S. STOCKS ON THE MOVE-ATMC, G-III Apparel, Cognyte
Reuters  ·  12-09
BUZZ-U.S. STOCKS ON THE MOVE-ATMC, G-III Apparel, Cognyte
Vor Biopharma Shares up 13% After JP Morgan Initiates Coverage With 'Overweight'
THOMSON REUTERS  ·  12-09
Vor Biopharma Shares up 13% After JP Morgan Initiates Coverage With 'Overweight'
Vor Biopharma Cuts Stock Option Exercise Price to $8.18 for Executives
Reuters  ·  12-09
Vor Biopharma Cuts Stock Option Exercise Price to $8.18 for Executives
BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Ares Management, Vor Bio
Reuters  ·  12-09
BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Ares Management, Vor Bio
Top Premarket Gainers
MT Newswires Live  ·  12-09
Top Premarket Gainers
BUZZ-Vor Bio jumps as J.P.Morgan initiates with 'overweight' rating
Reuters  ·  12-09
BUZZ-Vor Bio jumps as J.P.Morgan initiates with 'overweight' rating
Vor Biopharma Shares Jump 67% Premarket After JP Morgan Initiates Coverage With 'Overweight'
THOMSON REUTERS  ·  12-09
Vor Biopharma Shares Jump 67% Premarket After JP Morgan Initiates Coverage With 'Overweight'
Vor Biopharma Coverage Assumed by Wedbush at Neutral
Dow Jones  ·  11-25
Vor Biopharma Coverage Assumed by Wedbush at Neutral
Vor Biopharma (VOR) Gets a Hold from Wedbush
TIPRANKS  ·  11-25
Vor Biopharma (VOR) Gets a Hold from Wedbush
Wedbush Boosts Price Target on Vor Biopharma to $9 From $0.40, Keeps Neutral Rating
MT Newswires Live  ·  11-25
Wedbush Boosts Price Target on Vor Biopharma to $9 From $0.40, Keeps Neutral Rating
Vor Biopharma Reports Q3 2025 Financial Results and Strategic Updates
TIPRANKS  ·  11-18
Vor Biopharma Reports Q3 2025 Financial Results and Strategic Updates
No data available

Introduction

Company Name.
Vor Biopharma Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Issue price:
--